GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Gross Profit

Peptron (XKRX:087010) Gross Profit : ₩929 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Gross Profit?

Peptron's gross profit for the three months ended in Mar. 2024 was ₩76 Mil. Peptron's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₩929 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Peptron's gross profit for the three months ended in Mar. 2024 was ₩76 Mil. Peptron's Revenue for the three months ended in Mar. 2024 was ₩477 Mil. Therefore, Peptron's Gross Margin % for the quarter that ended in Mar. 2024 was 15.96%.

Peptron had a gross margin of 15.96% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 10 years, the highest Gross Margin % of Peptron was 68.58%. The lowest was 32.62%. And the median was 37.72%.


Peptron Gross Profit Historical Data

The historical data trend for Peptron's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Gross Profit Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 656.65 1,136.29 4,543.12 3,319.84 1,140.58

Peptron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.89 238.86 234.20 379.63 76.20

Competitive Comparison of Peptron's Gross Profit

For the Biotechnology subindustry, Peptron's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Gross Profit distribution charts can be found below:

* The bar in red indicates where Peptron's Gross Profit falls into.



Peptron Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Peptron's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3341.894 - 2201.314
=1,141

Peptron's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=477.267 - 401.072
=76

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩929 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Peptron's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=76 / 477.267
=15.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Peptron  (XKRX:087010) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Peptron had a gross margin of 15.96% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Peptron Gross Profit Related Terms

Thank you for viewing the detailed overview of Peptron's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron (XKRX:087010) Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines